



HAL
open science

Endocannabinoid-Mediated Plasticity in Nucleus Accumbens Controls Vulnerability to Anxiety after Social Defeat Stress

Olivier Manzoni, Clémentine Bosch-Bouju, Thomas Larrieu, Louisa Linders,
Olivier J. Manzoni, Sophie Layé

► **To cite this version:**

Olivier Manzoni, Clémentine Bosch-Bouju, Thomas Larrieu, Louisa Linders, Olivier J. Manzoni, et al.. Endocannabinoid-Mediated Plasticity in Nucleus Accumbens Controls Vulnerability to Anxiety after Social Defeat Stress. *Cell Reports*, 2016, 16 (5), pp.1237 - 1242. 10.1016/j.celrep.2016.06.082 . hal-01826144

HAL Id: hal-01826144

<https://hal.science/hal-01826144>


Submitted on 27 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Endocannabinoid-Mediated Plasticity in Nucleus Accumbens Controls Vulnerability to Anxiety after Social Defeat Stress

Graphical Abstract



Authors

Clémentine Bosch-Bouju,
 Thomas Larrieu, Louisa Linders,
 Olivier J. Manzoni, Sophie Layé

Correspondence

olivier.manzoni@inserm.fr (O.J.M.),
 sophie.laye@bordeaux.inra.fr (S.L.)

In Brief

Bosch-Bouju et al. used cluster analysis to segregate mice into anxious and non-anxious populations following social defeat. Endocannabinoid spike-timing-dependent plasticity is abolished in anxious mice only. Enhancement of endocannabinoid signaling in the nucleus accumbens restores anxiety-like behaviors and synaptic plasticity. Endocannabinoid plasticity is thus a synaptic marker of anxiety following social defeat.

Highlights

- Socially defeated mice were clustered into anxious and non-anxious groups
- Spike-timing endocannabinoid plasticity was abolished in anxious mice
- Elevation of 2-AG levels in the nucleus accumbens restores behavior and plasticity
- Endocannabinoid plasticity is a synaptic marker of anxiety following social defeat

Endocannabinoid-Mediated Plasticity in Nucleus Accumbens Controls Vulnerability to Anxiety after Social Defeat Stress

Clémentine Bosch-Bouju,^{1,2,6} Thomas Larrieu,^{1,2,6} Louisa Linders,^{1,2} Olivier J. Manzoni,^{3,4,5,7,*} and Sophie Layé^{1,2,7,*}

¹Nutrition et Neurobiologie Intégrée, UMR 1286, INRA, 33000 Bordeaux, France

²Nutrition et Neurobiologie Intégrée, UMR 1286, Bordeaux University, 33000 Bordeaux, France

³Aix-Marseille Université, 13009 Marseille, France

⁴INSERM, 13009 Marseille, France

⁵INMED UMR S 901, 13009 Marseille, France

⁶Co-first author

⁷Co-senior author

*Correspondence: olivier.manzoni@inserm.fr (O.J.M.), sophie.laye@bordeaux.inra.fr (S.L.)

<http://dx.doi.org/10.1016/j.celrep.2016.06.082>

SUMMARY

Chronic social defeat stress (CSDS) is a clinically relevant model of mood disorders. The relationship between the CSDS model and a physiologically pertinent paradigm of synaptic plasticity is not known. Here, we found that cluster analysis of the emotional behavior states of mice exposed to CSDS allowed their segregation into anxious and non-anxious groups. Endocannabinoid-mediated spike-timing dependent plasticity (STDP) in the nucleus accumbens was attenuated in non-anxious mice and abolished in anxious mice. Anxiety-like behavior in stressed animals was specifically correlated with their ability to produce STDP. Pharmacological enhancement of 2-arachidonoyl glycerol (2-AG) signaling in the nucleus accumbens normalized the anxious phenotype and STDP in anxious mice. These data reveal that endocannabinoid modulation of synaptic efficacy in response to a naturalistic activity pattern is both a molecular correlate of behavioral adaptability and a crucial factor in the adaptive response to chronic stress.

INTRODUCTION

The neural and molecular mechanisms responsible for individual vulnerability and resilience to neuropsychiatric illnesses such as depression and anxiety disorders are poorly understood. Endocannabinoids have been linked to psychiatric illness, in particular the pathophysiology of depressive- and anxiety-like behaviors (Lafourcade et al., 2011; Hill and Gorzalka, 2009; Hillard et al., 2012; Mangieri and Piomelli, 2007; Mechoulam and Parker, 2013; Vinod and Hungund, 2006). In depressed patients, blood levels of endocannabinoids (eCBs) are decreased (Hill et al., 2009), while in animal models of depression, altered brain levels of eCBs and functionality of the cannabinoid type 1 receptor

(CB1R) are reported (Bluett et al., 2014; Hill et al., 2005; Qin et al., 2015). In addition, pharmacological and genetic disruption of CB1R or eCB production results in enhanced anxiety, stress, and fear response (Hill and Patel, 2013; Jenniches et al., 2016; Marsicano et al., 2002; Qin et al., 2015; Shonesy et al., 2014; Steiner et al., 2008), reinforcing the idea that this system may play a significant role in the pathogenesis of neuropsychiatric diseases.

Endocannabinoids are lipid mediators with essential modulatory functions in the brain (Katona and Freund, 2012). Produced in the postsynapse, the two major eCBs, anandamide and 2-arachidonoyl glycerol (2-AG), signal in a retrograde direction to modulate synaptic strength via presynaptic CB1R (Castillo et al., 2012). By integrating and translating environmental changes into synaptic changes, eCBs regulate a range of brain functions (for review, see Morena et al., 2016). Activation of CB1R leads to acute depression of synaptic transmission, which with extended eCB signaling engages an endocannabinoid-mediated long-term depression (LTD) originally discovered in the nucleus accumbens (Robbe et al., 2002), a key structure to stress resiliency (Duval et al., 2015; Francis et al., 2015; Levita et al., 2012; McLaughlin et al., 2014; Vialou et al., 2010). However, it is not known whether eCBs produced in response to a naturalistic pattern of synaptic activity participate in stress resiliency.

Here, we focused on eCB spike-timing dependent plasticity (STDP) at excitatory synapses in the accumbens in a clinically relevant model of anxiety- and depressive-like behaviors: chronic social defeat stress (CSDS) (Berton et al., 2006; Krishnan et al., 2007; Larrieu et al., 2014). CSDS induces individual differences across behavioral endpoints (Krishnan et al., 2007). We automated classification of behavioral endpoints to segregate defeated mice based on their anxiety-like behaviors. Our findings demonstrate that impairment of eCB STDP in the accumbens is a synaptic signature of anxiety-like behavior after social defeat stress. The restoration of eCB signaling in the accumbens through the enhancement of 2-AG signaling protects against CSDS-induced anxiety-like behavior. Altogether, these data establish eCB STDP in the accumbens as a central regulator of adaptive capacity in animals exposed to CSDS, offering a






Figure 1. Behavioral Clustering in Socially Defeated Mice

(A–D) Behavioral portraits of undefeated mice (white) and defeated mice (red) show increased anxiety in defeated mice. $*p < 0.05$, unpaired t test. Data are presented as mean \pm SEM. (A) Time in the interaction zone. Undefeated: 127 ± 11 s, n = 19; defeated: 96 ± 8 s, n = 34. $t_{51} = 2.336$, $*p = 0.0235$. (B) Time in the center of the open field. Undefeated: $11.3\% \pm 1.2\%$, n = 19; defeated: $9.0\% \pm 0.8\%$, n = 36. $t_{53} = 1.570$, $p = 0.1223$. (C) Time in the light compartment. Undefeated: 260 ± 16 s, n = 19; defeated: 198 ± 12 s, n = 37. $t_{54} = 3.048$, $*p = 0.036$. (D) Time in open arms of the elevated plus maze. Undefeated: $17.5\% \pm 1.4\%$, n = 19; defeated: $13.2\% \pm 1.1\%$, n = 37. $t_{54} = 2.385$, $*p = 0.0208$. (E) Clustering analysis of socially defeated mice's behavior reveals a dendrogram with two clusters corresponding to anxious animals (red) and non-anxious animals (black). (F) Normalized average values for all behavioral parameters of the cluster analysis in anxious and non-anxious groups. Data are presented as mean \pm SEM. From left to right, non-anxious (n = 18) versus anxious (n = 18), respectively: SA, social avoidance test, 0.60 ± 0.05 versus 0.54 ± 0.06 ; OF, open field test, 0.28 ± 0.05 versus 0.19 ± 0.04 ; L/D, light/dark box test, 0.72 ± 0.04 versus 0.44 ± 0.04 ; EPM, elevated plus maze test, 0.56 ± 0.04 versus 0.21 ± 0.03 . $*p < 0.05$, two-way ANOVA with Bonferroni post-test, with cluster ($F_{(1,105)} = 42.96$, $p < 0.0001$) and behavioral parameter ($F_{(3,105)} = 29.99$, $p < 0.0001$) as factors. Interaction: $F_{(3,105)} = 5.39$, $p = 0.0017$.

pharmacologically amenable mechanism to promote resiliency to stressful events.

RESULTS

Segregation of Defeated Animals into Anxious and Non-anxious Populations Using Cluster Analysis

Naive C57BL/6J mice were subjected to ten daily bouts of social defeat by an aggressive CD1 male mouse. CSDS is known to induce individual differences to stress responses, and defeated animals can be separated into susceptible and resilient based on the measure of their social interaction (Figure S1) (Golden et al., 2011; Krishnan et al., 2007). In the present study, we used an alternative method to segregate defeated mice based on their emotional behaviors in open field, social avoidance, light/dark box, and elevated plus maze tests (Figures 1A–1D; Figure S2). This unbiased cluster analysis approach revealed that defeated mice can be segregated into two populations based on their emotional behaviors (Figure 1E): 52% of defeated mice showed severe anxiety-like behaviors and were hereafter labeled anxious, while the remaining 48% that display anxiety-like behaviors similar to those of undefeated mice were labeled non-anxious. By comparison with the classical segregation of susceptible and resilient mice, we found that 50% of resilient and 55% of susceptible mice were anxious (Figure S1). Consequently, both anxious and non-anxious mice displayed an increase in social avoidance following CSDS, but only anxious

mice exhibited elevated anxiety-like behaviors, as revealed by an aversion to the open arms of an elevated plus maze and the light compartment of a light/dark box (Figure 1F; Figure S2). Anxious and non-anxious mice displayed a similar increase in plasma corticosterone levels, adrenal weight, and body weight (Figure S2), suggesting that the two populations of defeated mice do not differ in their metabolic stress response.

Endocannabinoid Spike-Timing Dependent Depression Covariates with Anxiety-like Behavior

We next analyzed the consequences of CSDS on synaptic Hebbian learning in the accumbens, a key structure that contributes to the etiology of mood and anxiety disorders (Bagot et al., 2015; Calhoun and Tye, 2015; Shin et al., 2015; Vialou et al., 2010). We first established that CB1R mediates Hebbian STDP (Abbott and Nelson, 2000; Fino et al., 2010) in the accumbens. In undefeated mice, presynaptic stimulation of 100 pairings at 1 Hz coupled to a single postsynaptic spike delayed by ~ 15 ms induced significant LTD (51% of baseline) of excitatory postsynaptic currents (EPSCs) (Figures 2A–2C). As expected for eCB-mediated plasticity, the CB1R antagonists AM251 and SR141716A both blocked STDP-LTD (Figure S3). In anxious mice, STDP-LTD was abolished (111% of baseline) (Figure 2A). Non-anxious mice displayed an intermediary phenotype: STDP-LTD was attenuated but still present (83% of baseline) (Figures 2A–2C). In the bed nucleus of the stria terminalis, stress transforms CB1R-dependent LTD to long-term potentiation




Figure 2. Spike-Timing-Dependent LTD is a Synaptic Marker in Anxious Mice

(A) Time course of STDP-LTD in undefeated (white), non-anxious (black), and anxious (red) mice. EPSC normalized amplitude 45 min after STDP. Undefeated: $51.28\% \pm 4.36\%$, $n = 16$; non-anxious: $82.13\% \pm 4.32\%$, $n = 18$; anxious: $110.80\% \pm 8.71\%$, $n = 18$. * $p < 0.05$, two-way ANOVA with Bonferroni post-test, with group ($F_{(2,512)} = 104.99$, $p < 0.0001$) and time ($F_{(10,512)} = 5.11$, $p < 0.0001$) as factors. Interaction: $F_{(20,512)} = 2.90$, $p < 0.0001$. Data are presented as mean \pm SEM. Illustration traces: example of ten averaged EPSCs during baseline (left) and 45 min after STDP (right). Upper (gray), undefeated; middle (black), non-anxious; bottom (red), anxious. Scale bar, 50 pA, 10 ms.

(B) Cumulative probability distribution of normalized EPSCs after STDP protocol. Same color code as (A).

(C) EPSCs before and after STDP-LTD induction for undefeated (white), non-anxious (black), and anxious (red) mice. No defeat: before, -177 ± 21 pA, versus after, -88 ± 14 pA; $n = 16$, $p < 0.0001$. Non-anxious: before, -181 ± 22 pA, versus after, -150 ± 22 pA; $n = 18$, $p = 0.0025$. Anxious: before, -175 ± 19 pA, versus after, -190 ± 26 pA; $n = 18$, $p = 0.3365$. Each line represents one neuron, * $p < 0.05$, paired t test.

(D) The anxiety score positively correlates with the expression of LTD ($r^2 = 0.1222$, $p = 0.0339$, Pearson test). Each dot represents one mouse.

(LTP) (Glangetas et al., 2013). Our data support this idea that the STDP protocol triggered LTD in all and 55% of the neurons from undefeated and non-anxious mice, respectively, in contrast to anxious mice, among which only 11% of the neurons expressed LTD and up to 33% exhibited LTP (LTD threshold, 85% of baseline EPSC; LTP threshold, 115%) (Figure 2B). To strengthen the association between eCB-mediated plasticity and anxiety, we computed an anxiety score and found that this behavioral index positively correlated with eCB-LTD in the accumbens (Figure 2D). Specifically, eCB-LTD was significantly correlated with anxiety measured in open field, light/dark box, and elevated plus maze tests (Table S1). In contrast, we did not observe a correlation between eCB-LTD and corticosterone levels in defeated mice (Figure S3). These data suggest that both groups experienced similar levels of neuroendocrine stress response and dissociate general hypothalamic-pituitary-adrenal axis reactivity to stress from social defeat stress-induced eCB-plasticity deficits. Basic intrinsic and synaptic properties of accumbens output neurons were similar in anxious and non-anxious mice (Figure S3), suggesting that modification of neuronal excitability or network activity is a minor contributor to the lack of eCB-mediated plasticity.

Pharmacological Enhancement of eCB Signaling Normalizes Both Anxiety-related Behavior and Synaptic Plasticity within the Accumbens

We next investigated whether upregulation of 2-AG signaling could normalize anxiety-like behavior and eCB-LTD in defeated mice. We used JZL184, a monoacylglycerol lipase (MAGL) inhibitor, to prevent 2-AG degradation and increase its accumulation

at the synapse (Jung et al., 2012). Mice treated with JZL184 (16 mg/kg, intraperitoneal [i.p.]) 1 day after the last session of CSDS showed anxiety-like behavior that was undistinguishable from that of undefeated mice (Figure 3A). To discern the contribution of 2-AG elevation within the accumbens in the systemic effects of JZL184, we repeated experiments directly infusing the MAGL inhibitor into the accumbens (1 μ g, 0.5 μ l/site). Similar to the systemic protocol, local infusion of JZL184 prevented anxiety-like behaviors in defeated mice (Figure 3C). We also found that JZL184 (1 μ M) restored eCB-LTD in defeated mice (Figures 3B–3D; Figure S3), reinforcing the link between eCB-mediated STDP-LTD in the accumbens and behavioral anxiety following CSDS. As a control, the effect of JZL184 on STDP-LTD was blocked by the CB1R antagonist SR141716A (Figure S3). Altogether, these data favor the idea that elevation of 2-AG in the accumbens can normalize anxiety behavior in defeated mice.

DISCUSSION

There is a considerable interest in understanding neurobiological correlates of adaptive response and resiliency to chronic social stress. In the current study, we provide clear evidence that eCB-mediated Hebbian learning at medium spiny neuron excitatory synapses in the nucleus accumbens contributes to behavioral adaptations to social stress. Furthermore, our results indicate that this synaptic plasticity is a pharmacologically targetable neurobiological mechanism that may promote resistance to anxiety following chronic stress.

A unique feature of CSDS, distinguishing it from other environmental stressors, is that CSDS induces a range of individual




Figure 3. Enhancement of Circulating 2-AG Normalizes Anxious Behavior and Synaptic Depression in Defeated Mice

(A) A single injection of JZL184 (16 mg/kg) is sufficient to restore a normal anxiety-like behavior. Elevated plus maze (EPM) score is the average of normalized measures for number of head dippings, percentage of time in the open arms, and number of entries in the open arms. Undepleted: 0.94 ± 0.13 , $n = 6$; defeated: 0.38 ± 0.09 , $n = 6$; undefeated + JZL184: 0.64 ± 0.04 , $n = 4$; defeated + JZL184: 0.67 ± 0.01 , $n = 3$. Two-way ANOVA with Bonferroni post-test, with JZL184 ($F_{(1,15)} = 0.0005$, $p = 0.9821$) and CSDS ($F_{(1,15)} = 5.983$, $p = 0.0273$) as factors. Interaction: $F_{(1,15)} = 7.713$, $p = 0.0141$. * $p < 0.05$.

(B) Infusion of JZL184 bilaterally in the nucleus accumbens also restores anxiety behavior of defeated mice. EPM score. Defeated: 0.39 ± 0.08 , $n = 7$; defeated + JZL184_{NAc}: 0.70 ± 0.06 , $n = 7$. $t_{13} = 3.158$, * $p = 0.0076$, unpaired t test.

(C) Time course of STDP-LTD in defeated mice without JZL184 (red) and with JZL184 (purple). EPSC normalized amplitude 45 min after STDP. Defeated: $96.88\% \pm 5.36\%$, $n = 36$; defeated + JZL184: $55.13\% \pm 4.96\%$, $n = 22$. * $p < 0.05$, two-way ANOVA with Bonferroni post-test, with JZL184 ($F_{(1,572)} = 140.07$, $p < 0.0001$) and time ($F_{(10,572)} = 8.08$, $p < 0.0001$) as factors. Interaction: $F_{(10,572)} = 4.02$, $p < 0.0001$. Illustration traces: example of ten averaged EPSCs during baseline (left) and 45 min after STDP (right). Scale bar, 100 pA, 10 ms. (A–C) Data are presented as mean \pm SEM.

responses (Golden et al., 2011; Krishnan et al., 2007) similar to those observed after traumatic stress in humans. This particularly makes CSDS in rodents a useful model for studying the mechanisms that underlie anxiety and depression onset. Here, we used several measures of emotional behavior to classify a population of CSDS-exposed mice into anxious and non-anxious groups using cluster analysis. Using this approach, we identified a non-anxious set of CSDS animals corresponding to approximately half of the entire population that failed to develop anxiety-related behavior and exhibited a behavioral phenotype comparable to that of undefeated mice. Both anxious and non-anxious mice showed strong generalized social avoidance. This study therefore reports individual differences in anxiety-like behaviors in mice exposed to CSDS. In the nucleus accumbens, CB1R is expressed at both excitatory and inhibitory synapses (Pickel et al., 2004). However, STDP protocol requires activation of pre- and post-synaptic elements of the stimulated synapses, which rules out the contribution of interneurons' plasticity in the observed STDP-LTD.

It has been previously reported that anxiety-like behavior may be correlated to levels of eCBs in the brain (Hill and Patel, 2013; Qin et al., 2015), but the effects on the eCB synaptic plasticity remained unexplored. In our study, we demonstrated that anxiety behavior induced by CSDS covariates with eCB-dependent plasticity. Here, we used a STDP protocol to reveal the functionality of the eCB system. Hebbian synaptic plasticity induced by STDP has been described in intact brains in the human cortex and in sensory systems and is thought to be a neurobiological basis for associative learning (Letzkus et al., 2007). However, the significance of STDP in non-sensory or motor systems remains to be clarified. We demonstrated that non-anxious mice display an attenuation in eCB STDP but that this form of plasticity is abolished in anxious mice. This suggests that eCB Hebbian plasticity constitutes a system for adaptive synaptic plasticity in the accumbens that allows behavioral adaptability and thus avoids the development of strong anxiety-like behavior following CSDS.

The role of the eCB system in stress and anxiety disorders may rely on its reciprocal interactions with the hypothalamic-pituitary-adrenal axis, which is responsible for stress response in the body (Gorzalka and Hill, 2009; Hill and Tasker, 2012; McEwen et al., 2015). It has been previously shown that stress-induced modulation of corticosterone affects the eCB system in the amygdala and the hypothalamus (Gray et al., 2015; Qin et al., 2015; Wamsteeker et al., 2010). In the current study, basal corticosterone levels were increased in both anxious and non-anxious defeated groups, without apparent correlation to the level of eCB-LTD. Whether hypothalamic-pituitary-adrenal axis reactivity due to acute stress might be different between groups has yet to be determined, but this is a focus of future research for our group. Recent findings report preexisting individual differences in the peripheral immune system that

(D) EPSC amplitude before and after STDP protocol for defeated mice with JZL184 bath application. Before, -233 ± 32 pA, versus after, -131 ± 25 pA; $n = 22$, * $p < 0.0001$, paired t test. Each line represents one neuron.

(E) Cumulative probability distribution of normalized EPSCs after STDP protocol. Same color code as (C).

predict and promote stress susceptibility (Hodes et al., 2014). In our study, innate differences in the functionality of the eCB system could be responsible for vulnerability to social defeat-induced emotional alteration.

The lack of eCB plasticity in anxious mice may arise from reduced eCB levels. Reduction in circulating levels of the eCB 2-AG has been found in individuals exposed to traumatic stress, as well as in rodents exposed to chronic stress (Hill et al., 2009), while enhancement of 2-AG levels increases behavioral resiliency to chronic stress in mice (Zhang et al., 2015; Zhong et al., 2014). Thus, we tested whether increased anxiety-related behavior could be overcome by enhancing 2-AG signaling, the main endocannabinoid involved in LTD in the accumbens (Castillo et al., 2012). We found that pharmacological blockade of intracellular 2-AG hydrolysis in mice subjected to CSDS alleviated the anxiety-related behavior and restored eCB-dependent plasticity in a CB1R-dependent manner. This suggests that CSDS-induced anxiety alters the bioavailability of eCB.

In conclusion, we found that impairment of eCB plasticity in the accumbens is a synaptic signature for behavioral adaptability following social stress. The restoration of eCB signaling through the improvement of 2-AG signaling protects against CSDS-induced anxiety-like behavior. Finally, exploring emotional processes at the synaptic level would lead to a better understanding of how chronic stress affects our brain and offer a pharmacologically amenable mechanism to promote resiliency to stressful events.

EXPERIMENTAL PROCEDURES

CSDS and Behavioral Testing

All experiments were performed according to criteria of the European Communities Council Directive (50120103-A) on C57BL/6J adult male mice. The social defeat protocol was performed as previously described (Larrieu et al., 2014). Behavioral tests were performed 24–48 hr after the last session of social defeat using a social avoidance test, open field test, light/dark box test, and elevated plus maze test (see supplemental Information for details).

The anxiety score was calculated as the algebraic sum of standardized scores $(x - \text{min value}) / (\text{max value} - \text{min value})$ of each of the six analyzed parameters of the three anxiety-related behavior tests. When more than one parameter was used for one test, normalized values of parameters were averaged so that the power of each of the three anxiety tests was equal to 1. This procedure yields scores that are distributed along a scale from 0 to 3, with 3 reflecting high anxiety.

Electrophysiology

Brain slices were prepared 24 hr after the last behavioral test for each animal. Signals were amplified and recorded with Multiclamp 700B, controlled with pClamp 10.3 software via a Digidata 1440A interface (Molecular Devices). STDP protocol consists of pairing pre- and postsynaptic stimulations 100 times at 1 Hz, with a delay of ~ 15 ms and the neuron held at -70 mV in the current clamp configuration. Medium spiny neurons were recorded for 10 min of stable baseline (0.1 Hz) and for at least 35 min after the STDP protocol. Chemicals used were AM251 (4 μM), SR141716A (1 μM), and JZL184 (1 μM).

In Vivo Pharmacological Experiments

For JZL184 i.p. injections, mice were given i.p. injections of vehicle (22.5:100 HBC:H₂O) or JZL184 (16 mg/kg) 6 hr before the elevated plus maze test. For JZL injections in the nucleus accumbens, animals were implanted 1 week before CSDS started with bilateral guide cannulas (PlasticsOne) 1 mm above the nucleus accumbens. JZL184 (1 $\mu\text{g}/0.5 \mu\text{l}$ DMSO 10% in saline/hemisphere)

or vehicle was injected into the nucleus accumbens 1 hr before the elevated plus maze test.

Statistical Analyses

Statistical tests were performed with Prism (GraphPad) using a critical probability of $p < 0.05$. All values are given as mean \pm SEM. The dendrogram was obtained with XLStat (Addinsoft) using centroid hierarchical cluster analysis (Euclidean distance and Ward method) to separate the defeated mice into anxious and non-anxious phenotypes. See Supplemental Information for details.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, three figures, and one table and can be found with this article online at <http://dx.doi.org/10.1016/j.celrep.2016.06.082>.

AUTHOR CONTRIBUTIONS

Conceptualization, C.B.-B., T.L., O.J.M., and S.L.; Methodology, C.B.-B., T.L., and S.L.; Investigation, C.B.-B., T.L., and L.L.; Writing C.B.-B., T.L., O.J.M. and S.L., Funding Acquisition, S.L. and O.J.M.; Supervision, S.L. and O.J.M.

ACKNOWLEDGMENTS

This research was financially supported by INRA, Agence Nationale de la Recherche (ANR-MoodFood), FRM, and the Region Aquitaine. T.L. was the recipient of a postdoctoral fellowship from the Société Française de Nutrition and the Labex BRAIN. C.B.-B. was funded by ANR-MoodFood and the European Agreenskills program (COFOUND FP7-267196). The authors thank Claudine Tridon, Cindy Testa, and Mathieu Cadet of the animal facility. We thank Pierre Trifilieff, Agnès Nadjar, and Corinne Joffre for helpful and fruitful discussions and Dr. Henry Martin for proofreading the manuscript.

Received: November 19, 2015

Revised: May 18, 2016

Accepted: June 21, 2016

Published: July 21, 2016

REFERENCES

- Abbott, L.F., and Nelson, S.B. (2000). Synaptic plasticity: taming the beast. *Nat. Neurosci.* 3 (Suppl), 1178–1183.
- Bagot, R.C., Parise, E.M., Peña, C.J., Zhang, H.-X., Maze, I., Chaudhury, D., Persaud, B., Cacho, R., Bolaños-Guzmán, C.A., Cheer, J.F., et al. (2015). Ventral hippocampal afferents to the nucleus accumbens regulate susceptibility to depression. *Nat. Commun.* 6, 7062.
- Berton, O., McClung, C.A., Dileone, R.J., Krishnan, V., Renthal, W., Russo, S.J., Graham, D., Tsankova, N.M., Bolanos, C.A., Rios, M., et al. (2006). Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. *Science* 311, 864–868.
- Bluett, R.J., Gamble-George, J.C., Hermanson, D.J., Hartley, N.D., Marnett, L.J., and Patel, S. (2014). Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. *Transl. Psychiatry* 4, e408.
- Calhoun, G.G., and Tye, K.M. (2015). Resolving the neural circuits of anxiety. *Nat. Neurosci.* 18, 1394–1404.
- Castillo, P.E., Younts, T.J., Chávez, A.E., and Hashimoto, Y. (2012). Endocannabinoid signaling and synaptic function. *Neuron* 76, 70–81.
- Duval, E.R., Javanbakht, A., and Liberzon, I. (2015). Neural circuits in anxiety and stress disorders: a focused review. *Ther. Clin. Risk Manag.* 11, 115–126.
- Fino, E., Paille, V., Cui, Y., Morera-Herreras, T., Deniau, J.-M., and Venance, L. (2010). Distinct coincidence detectors govern the corticostriatal spike timing-dependent plasticity. *J. Physiol.* 588, 3045–3062.
- Francis, T.C., Chandra, R., Friend, D.M., Finkel, E., Dayrit, G., Miranda, J., Brooks, J.M., Iñiguez, S.D., O'Donnell, P., Kravitz, A., and Lobo, M.K.

- (2015). Nucleus accumbens medium spiny neuron subtypes mediate depression-related outcomes to social defeat stress. *Biol. Psychiatry* *77*, 212–222.
- Glangetas, C., Girard, D., Groc, L., Marsicano, G., Chaulouff, F., and Georges, F. (2013). Stress switches cannabinoid type-1 (CB1) receptor-dependent plasticity from LTD to LTP in the bed nucleus of the stria terminalis. *J. Neurosci.* *33*, 19657–19663.
- Golden, S.A., Covington, H.E., 3rd, Berton, O., and Russo, S.J. (2011). A standardized protocol for repeated social defeat stress in mice. *Nat. Protoc.* *6*, 1183–1191.
- Gorzalka, B.B., and Hill, M.N. (2009). Integration of endocannabinoid signaling into the neural network regulating stress-induced activation of the hypothalamic-pituitary-adrenal axis. *Curr. Top. Behav. Neurosci.* *1*, 289–306.
- Gray, J.M., Vecchiarelli, H.A., Morena, M., Lee, T.T.Y., Hermanson, D.J., Kim, A.B., McLaughlin, R.J., Hassan, K.I., Kühne, C., Wotjak, C.T., et al. (2015). Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. *J. Neurosci.* *35*, 3879–3892.
- Hill, M.N., and Gorzalka, B.B. (2009). The endocannabinoid system and the treatment of mood and anxiety disorders. *CNS Neurol. Disord. Drug Targets* *8*, 451–458.
- Hill, M.N., and Patel, S. (2013). Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. *Biol. Mood Anxiety Disord.* *3*, 19.
- Hill, M.N., and Tasker, J.G. (2012). Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. *Neuroscience* *204*, 5–16.
- Hill, M.N., Patel, S., Carrier, E.J., Rademacher, D.J., Ormerod, B.K., Hillard, C.J., and Gorzalka, B.B. (2005). Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. *Neuropsychopharmacology* *30*, 508–515.
- Hill, M.N., Miller, G.E., Carrier, E.J., Gorzalka, B.B., and Hillard, C.J. (2009). Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. *Psychoneuroendocrinology* *34*, 1257–1262.
- Hillard, C.J., Weinlander, K.M., and Stuhr, K.L. (2012). Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. *Neuroscience* *204*, 207–229.
- Hodes, G.E., Pfau, M.L., Leboeuf, M., Golden, S.A., Christoffel, D.J., Bregman, D., Rebusi, N., Heshmati, M., Aleyasin, H., Warren, B.L., et al. (2014). Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. *Proc. Natl. Acad. Sci. USA* *111*, 16136–16141.
- Jenniches, I., Ternes, S., Albayram, O., Otte, D.M., Bach, K., Bindila, L., Michel, K., Lutz, B., Bilkei-Gorzo, A., and Zimmer, A. (2016). Anxiety, stress, and fear response in mice with reduced endocannabinoid levels. *Biol. Psychiatry* *79*, 858–868.
- Jung, K.-M., Sepers, M., Henstridge, C.M., Lassalle, O., Neuhofer, D., Martin, H., Ginger, M., Frick, A., DiPatrizio, N.V., Mackie, K., et al. (2012). Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. *Nat. Commun.* *3*, 1080.
- Katona, I., and Freund, T.F. (2012). Multiple functions of endocannabinoid signaling in the brain. *Annu. Rev. Neurosci.* *35*, 529–558.
- Krishnan, V., Han, M.-H., Graham, D.L., Berton, O., Renthal, W., Russo, S.J., Laplant, Q., Graham, A., Lutter, M., Lagace, D.C., et al. (2007). Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. *Cell* *131*, 391–404.
- Lafourcade, M., Larrieu, T., Mato, S., Duffaud, A., Sepers, M., Matias, I., De Smedt-Peyrusse, V., Labrousse, V.F., Bretillon, L., Matute, C., et al. (2011). Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. *Nat. Neurosci.* *14*, 345–350.
- Larrieu, T., Hilal, M.L., Fourrier, C., De Smedt-Peyrusse, V., Sans, N., Capuron, L., and Layé, S. (2014). Nutritional omega-3 modulates neuronal morphology in the prefrontal cortex along with depression-related behaviour through corticosterone secretion. *Transl. Psychiatry* *4*, e437.
- Letzkus, J.J., Kampa, B.M., and Stuart, G.J. (2007). Does spike timing-dependent synaptic plasticity underlie memory formation? *Clin. Exp. Pharmacol. Physiol.* *34*, 1070–1076.
- Levita, L., Hoskin, R., and Champi, S. (2012). Avoidance of harm and anxiety: a role for the nucleus accumbens. *Neuroimage* *62*, 189–198.
- Mangieri, R.A., and Piomelli, D. (2007). Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. *Pharmacol. Res.* *56*, 360–366.
- Marsicano, G., Wotjak, C.T., Azad, S.C., Bisogno, T., Rammes, G., Cascio, M.G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002). The endogenous cannabinoid system controls extinction of aversive memories. *Nature* *415*, 530–534.
- McEwen, B.S., Bowles, N.P., Gray, J.D., Hill, M.N., Hunter, R.G., Karatsoreos, I.N., and Nasca, C. (2015). Mechanisms of stress in the brain. *Nat. Neurosci.* *18*, 1353–1363.
- McLaughlin, R.J., Hill, M.N., and Gorzalka, B.B. (2014). A critical role for prefrontocortical endocannabinoid signaling in the regulation of stress and emotional behavior. *Neurosci. Biobehav. Rev.* *42*, 116–131.
- Mechoulam, R., and Parker, L.A. (2013). The endocannabinoid system and the brain. *Annu. Rev. Psychol.* *64*, 21–47.
- Morena, M., Patel, S., Bains, J.S., and Hill, M.N. (2016). Neurobiological interactions between stress and the endocannabinoid system. *Neuropsychopharmacology* *41*, 80–102.
- Pickel, V.M., Chan, J., Kash, T.L., Rodríguez, J.J., and MacKie, K. (2004). Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. *Neuroscience* *127*, 101–112.
- Qin, Z., Zhou, X., Pandey, N.R., Vecchiarelli, H.A., Stewart, C.A., Zhang, X., Lagace, D.C., Brunel, J.M., Béique, J.-C., Stewart, A.F.R., et al. (2015). Chronic stress induces anxiety via an amygdalar intracellular cascade that impairs endocannabinoid signaling. *Neuron* *85*, 1319–1331.
- Robbe, D., Kopf, M., Remaury, A., Bockaert, J., and Manzoni, O.J. (2002). Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. *Proc. Natl. Acad. Sci. USA* *99*, 8384–8388.
- Shin, S., Kwon, O., Kang, J.I., Kwon, S., Oh, S., Choi, J., Kim, C.H., and Kim, D.G. (2015). mGluR5 in the nucleus accumbens is critical for promoting resilience to chronic stress. *Nat. Neurosci.* *18*, 1017–1024.
- Shonesy, B.C., Bluett, R.J., Ramikie, T.S., Báldi, R., Hermanson, D.J., Kingsley, P.J., Marnett, L.J., Winder, D.G., Colbran, R.J., and Patel, S. (2014). Genetic disruption of 2-arachidonoylglycerol synthesis reveals a key role for endocannabinoid signaling in anxiety modulation. *Cell Rep.* *9*, 1644–1653.
- Steiner, M.A., Wanisch, K., Monory, K., Marsicano, G., Borroni, E., Bächli, H., Holsboer, F., Lutz, B., and Wotjak, C.T. (2008). Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. *Pharmacogenomics* *9*, 196–208.
- Vialou, V., Robison, A.J., Laplant, Q.C., Covington, H.E., 3rd, Dietz, D.M., Ohnishi, Y.N., Mouzon, E., Rush, A.J., 3rd, Watts, E.L., Wallace, D.L., et al. (2010). DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses. *Nat. Neurosci.* *13*, 745–752.
- Vinod, K.Y., and Hungund, B.L. (2006). Role of the endocannabinoid system in depression and suicide. *Trends Pharmacol. Sci.* *27*, 539–545.
- Wamsteeker, J.I., Kuzmiski, J.B., and Bains, J.S. (2010). Repeated stress impairs endocannabinoid signaling in the paraventricular nucleus of the hypothalamus. *J. Neurosci.* *30*, 11188–11196.
- Zhang, Z., Wang, W., Zhong, P., Liu, S.J., Long, J.Z., Zhao, L., Gao, H.Q., Cravatt, B.F., and Liu, Q.S. (2015). Blockade of 2-arachidonoylglycerol hydrolysis produces antidepressant-like effects and enhances adult hippocampal neurogenesis and synaptic plasticity. *Hippocampus* *25*, 16–26.
- Zhong, P., Wang, W., Pan, B., Liu, X., Zhang, Z., Long, J.Z., Zhang, H.T., Cravatt, B.F., and Liu, Q.S. (2014). Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling. *Neuropsychopharmacology* *39*, 1763–1776.